RAVI KUMAR SINGAREDDY: Open Payments
NPI 1407809122 · SUWANEE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$808 in 37 payments from 14 companies in 2025. Trend: 2023 $226 · 2024 $409 · 2025 $808
Food & beverage: $808
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 8 | $203 |
| Neurocrine BioSciences, Inc. | 5 | $107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| ABBVIE INC. | 4 | $73 |
| Vanda Pharmaceuticals Inc. | 3 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $58 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| QOL Medical, LLC | 1 | $30 |
| E.R. Squibb & Sons, L.L.C. | 1 | $29 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $24 |
Products named: INVEGA SUSTENNA, TRINTELLIX, INGREZZA, VRAYLAR, CAPLYTA, REXULTI, SPRAVATO, HETLIOZ.
Industry payments across GA — which companies pay providers there.
